FDA approves oral solution Cuvposa for chronic drooling in children

07/29/2010 | Modern Medicine

The FDA approved Shionogi Pharma's Cuvposa, a flavored liquid form of glycopyrrolate, for the treatment of chronic drooling in patients ages 3 to 16 with neuromuscular disorders. Glycopyrrolate has long been approved for patients with peptic ulcers and to reduce salivation among those under anesthesia.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY